Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)

NCT06010329 is registered in ClinicalTrials.gov with Teligene US as lead sponsor.

NCT NCT06010329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06010329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)
Lead sponsor
Teligene US
Phase
Phase 2
Overall status
Recruiting
Start date
December 27, 2023
Completion date
December 31, 2028
Enrollment
66 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer